Pemetrexed
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Intraepithelial Neoplasia
Conditions
Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female
Trial Timeline
Feb 1, 2005 → Oct 1, 2007
NCT ID
NCT00190983About Pemetrexed
Pemetrexed is a phase 2 stage product being developed by Eli Lilly for Cervical Intraepithelial Neoplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT00190983. Target conditions include Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00035061 | Phase 2 | Completed |
| NCT03955042 | Phase 1 | Completed |
| NCT01473563 | Phase 2 | Completed |
| NCT00916630 | Phase 1 | Completed |
| NCT00732303 | Phase 2 | Terminated |
| NCT00864513 | Phase 2 | Terminated |
| NCT00520936 | Phase 2 | Completed |
| NCT00523419 | Phase 2 | Completed |
| NCT00540241 | Pre-clinical | Completed |
| NCT00497770 | Pre-clinical | Completed |
| NCT00316225 | Phase 2 | Completed |
| NCT00380718 | Approved | Completed |
| NCT00377520 | Phase 2 | Completed |
| NCT00190918 | Phase 2 | Completed |
| NCT00330915 | Phase 2 | Completed |
| NCT00109096 | Phase 2 | Completed |
| NCT00106002 | Phase 2 | Completed |
| NCT00216099 | Phase 2 | Completed |
| NCT00190983 | Phase 2 | Completed |
| NCT00216216 | Phase 2 | Terminated |
Competing Products
20 competing products in Cervical Intraepithelial Neoplasia